Northpointe Bancshares, Inc. Announces Appointment of Rodney E. Hood to its Board of Directors
Businesswire· 2026-02-27 14:20
Northpointe Bancshares, Inc. Announces Appointment of Rodney E. Hood to its Board of DirectorsFeb 27, 2026 9:20 AM Eastern Standard Time# Northpointe Bancshares, Inc. Announces Appointment of Rodney E. Hood to its Board of DirectorsShare---GRAND RAPIDS, Mich.--([BUSINESS WIRE])--Northpointe Bancshares, Inc. (NYSE: NPB) (the "Company†), announced today that the Honorable Rodney E. Hood has been appointed to the Board of Directors of the Company and its subsidiary, Northpointe Bank, effective February 27, 2 ...
Circle (CRCL) CFO Talks Earnings & Bullish Crypto Outlook
Youtube· 2026-02-27 14:19
Circle reported earnings earlier this week, beating expectations, and the shares have had quite the run this week to discuss the report and developments since its IPO last year. We want to welcome in our next guest. That's Jeremy Fox, CFO of Circle.Jeremy, thank you so much for joining us. Uh, great quarter. I mean, the EPS number strong, much stronger than expected, sizable beat there.Revenue better than expected, 770 million. Take us through just some of the highlights really quickly. >> Good morning, Dia ...
FormFactor: Don't Fear The Valuation, The HBM4 Earnings Inflection Is Here
Seeking Alpha· 2026-02-27 14:19
Core Insights - FormFactor, Inc. (FORM) has demonstrated strong stock performance, increasing by 75% year-to-date (YTD) [1] Group 1: Company Performance - The stock has been on a strong upward trend since reporting Q4 2025 earnings on February 4th [1]
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
Prnewswire· 2026-02-27 14:19
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies [Accessibility Statement] Skip NavigationSpinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platformLead candidates ATR 1072 and ATR 1086 expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectivelySAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ...
Delta Identifies Three Significant Gold Anomalies From the 2024-25 I-Zone Sector Till Survey and Reports Drill Results From the Latest Regional Exploration Drill Program
TMX Newsfile· 2026-02-27 14:18
Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Delta Resources Limited (TSXV: DLTA) (OTC Pink: DTARF) (FSE: 6GO1) ("Delta" or "the Company") is pleased to report the preliminary interpretation from the 2024-25 till survey conducted by IOS Géosciences in the I-Zone sector, located approximately 18 kilometres southwest of the Eureka Gold Deposit and about 60 kilometres west of Thunder Bay, Ontario. The till survey, completed in the fall of 2025 (see September 17, 2025 news release), has identified ...
Weekly Buzz: MGNX's LINNET Trial On Hold; ETON, ALUR Get FDA Nod; GILD Snaps Up ACLX
RTTNews· 2026-02-27 14:17
This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results were reported across multiple therapeutic areas, including radiographic and non-radiographic axial spondyloarthritis, microcystic lymphatic malformations, pulmonary arterial hypertension, and obesity. Here's a closer look at the details. FDA Approvals & Rejections Armata Pharma Secures FDA QIDP Designation for AP-SA02 Armata Pharmaceuticals, ...
Netflix Stock Ready For 50% Surge
247Wallst· 2026-02-27 14:16
Group 1 - Netflix stock is poised for a 50% surge, potentially rising from $90 to $135, following its decision to walk away from an $83 billion offer for Warner Bros. Discovery [1] - Analysts have upgraded Netflix's stock, with Wells Fargo raising its target price by 23% and Pivotal Research Group increasing it by 19%, citing strong subscriber growth and compelling entertainment value [1] - In Q2, Netflix reported a 16% year-over-year revenue increase to $11.1 billion, with diluted EPS rising from $4.88 to $7.19 and operating margins growing from 27.2% to 31.5% [1] Group 2 - Netflix's revenue increased by 18% year-over-year in Q4, crossing the 325 million paid memberships milestone, with operating income rising by 30% [1] - The company is recognized as the leading streaming service in the U.S. and is expected to maintain its momentum without significant changes in its operational strategy [1] - Netflix's advertising revenue is growing, indicating a shift beyond its traditional subscriber-supported model [1]
Gogo (GOGO) Reports Q4 Loss, Tops Revenue Estimates
ZACKS· 2026-02-27 14:16
Gogo (GOGO) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -166.67%. A quarter ago, it was expected that this in-flight internet provider would post earnings of $0.07 per share when it actually produced earnings of $0.1, delivering a surprise of +42.86%.Over the last four quarters, the company has ...
Fulgent Genetics, Inc. (FLGT) Q4 Earnings Top Estimates
ZACKS· 2026-02-27 14:16
Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +433.33%. A quarter ago, it was expected that this company would post a loss of $0.24 per share when it actually produced earnings of $0.14, delivering a surprise of +158.33%.Over the last four quarters, the ...
3 Investments Quietly Earning Boomers a Safe Profit
Yahoo Finance· 2026-02-27 14:15
Crypto is for kids, but what is there for seniors? As baby boomers continue to retire and live out their lives of leisure, retirement priorities shift from aggressive growth to capital preservation. No fuss, no muss. Successful retirement investing isn’t necessarily about catching lightning in a bottle; it’s about protecting all your nest eggs and all your baskets. If you can generate predictable income and stay ahead of inflation, you’re pretty much ahead of the game. These three investments may not be e ...